119 related articles for article (PubMed ID: 38081189)
1. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.
Dreher N; Dörrler AL; Kraus S; Higuchi T; Serfling SE; Samnick S; Einsele H; Grigoleit GU; Buck AK; Werner RA
Clin Nucl Med; 2024 Feb; 49(2):146-151. PubMed ID: 38081189
[TBL] [Abstract][Full Text] [Related]
2. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.
Buck AK; Grigoleit GU; Kraus S; Schirbel A; Heinsch M; Dreher N; Higuchi T; Lapa C; Hänscheid H; Samnick S; Einsele H; Serfling SE; Werner RA
J Nucl Med; 2023 Jan; 64(1):34-39. PubMed ID: 35738903
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.
Lapa C; Hänscheid H; Kircher M; Schirbel A; Wunderlich G; Werner RA; Samnick S; Kotzerke J; Einsele H; Buck AK; Wester HJ; Grigoleit GU
J Nucl Med; 2019 Jan; 60(1):60-64. PubMed ID: 29777009
[TBL] [Abstract][Full Text] [Related]
4. CXCR4-targeted theranostics in oncology.
Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
[TBL] [Abstract][Full Text] [Related]
5. Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.
Maurer S; Herhaus P; Lippenmeyer R; Hänscheid H; Kircher M; Schirbel A; Maurer HC; Buck AK; Wester HJ; Einsele H; Grigoleit GU; Keller U; Lapa C
J Nucl Med; 2019 Oct; 60(10):1399-1405. PubMed ID: 30850502
[TBL] [Abstract][Full Text] [Related]
6. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R; Haug A; Buske C; Heidegger S; Illert AL; Bassermann F; Herhaus P; Buck A; Duell J; Topp MS; Kraus S; Einsele H; Lapa C; Raderer M; Lenz G; Habringer S; von Tresckow B; Keller U
Nuklearmedizin; 2024 Apr; 63(2):57-61. PubMed ID: 38190998
[TBL] [Abstract][Full Text] [Related]
8. Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
Martin S; Viertl D; Janz A; Habringer S; Keller U; Schottelius M
EJNMMI Res; 2023 May; 13(1):40. PubMed ID: 37162652
[TBL] [Abstract][Full Text] [Related]
9. Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy.
Hartrampf PE; Kosmala A; Serfling SE; Bundschuh L; Higuchi T; Lapa C; Rowe SP; Matsusaka Y; Weich A; Buck AK; Bundschuh RA; Werner RA
Clin Nucl Med; 2023 Jun; 48(6):483-488. PubMed ID: 36947793
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging.
Kosmala A; Seifert S; Schneid S; Dreher N; Higuchi T; Weich A; Serfling SE; Hartrampf PE; Einsele H; Buck AK; Topp MS; Duell J; Werner RA
Mol Imaging Biol; 2023 Aug; 25(4):758-764. PubMed ID: 37286923
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
Chen Z; Xue Q; Yao S
Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
[TBL] [Abstract][Full Text] [Related]
12. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using
Buck AK; Haug A; Dreher N; Lambertini A; Higuchi T; Lapa C; Weich A; Pomper MG; Wester HJ; Zehndner A; Schirbel A; Samnick S; Hacker M; Pichler V; Hahner S; Fassnacht M; Einsele H; Serfling SE; Werner RA
J Nucl Med; 2022 Nov; 63(11):1687-1692. PubMed ID: 35241482
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
Green MM; Chao N; Chhabra S; Corbet K; Gasparetto C; Horwitz A; Li Z; Venkata JK; Long G; Mims A; Rizzieri D; Sarantopoulos S; Stuart R; Sung AD; Sullivan KM; Costa L; Horwitz M; Kang Y
J Hematol Oncol; 2016 Aug; 9(1):71. PubMed ID: 27535663
[TBL] [Abstract][Full Text] [Related]
14. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
Hartlapp I; Hartrampf PE; Serfling SE; Wild V; Weich A; Rasche L; Roth S; Rosenwald A; Mihatsch PW; Hendricks A; Wiegering A; Wiegering V; Hänscheid H; Schirbel A; Werner RA; Buck AK; Wester HJ; Einsele H; Kunzmann V; Lapa C; Kortüm KM
J Nucl Med; 2023 Sep; 64(9):1424-1430. PubMed ID: 37348915
[TBL] [Abstract][Full Text] [Related]
15.
Kraus S; Dierks A; Rasche L; Kertels O; Kircher M; Schirbel A; Zovko J; Steinbrunn T; Tibes R; Wester HJ; Buck AK; Einsele H; Kortüm KM; Rosenwald A; Lapa C
J Nucl Med; 2022 Jan; 63(1):96-99. PubMed ID: 34049979
[TBL] [Abstract][Full Text] [Related]
16. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [
Serfling SE; Lapa C; Dreher N; Hartrampf PE; Rowe SP; Higuchi T; Schirbel A; Weich A; Hahner S; Fassnacht M; Buck AK; Werner RA
Mol Imaging Biol; 2022 Aug; 24(4):659-665. PubMed ID: 35312939
[TBL] [Abstract][Full Text] [Related]
17. Outcome and safety of rechallenge [
Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
[TBL] [Abstract][Full Text] [Related]
18. Chemokine receptor - Directed imaging and therapy.
Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy.
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4077-4088. PubMed ID: 34041564
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
